NCT06005259View on ClinicalTrials.gov

Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX)

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

264

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

October 1, 2025

Study Completion Date

December 1, 2025

Conditions
CardiotoxicityNeoplasmsChemotherapy EffectHeart Failure
Interventions
DRUG

Spironolactone

Spironolactone 25 mg capsule

DRUG

Placebo

Placebo capsule

Trial Locations (1)

05403-000

Instituto do Coração, São Paulo

All Listed Sponsors
lead

University of Sao Paulo

OTHER

NCT06005259 - Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX) | Biotech Hunter | Biotech Hunter